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Gastrointestinal stromal tumour (GIST) is extremely rare with reported incidence of 20 per million per year. It is the 
most common mesenchymal tumour of the gastrointestinal tract. When it occurs at the pelvis in a female patient, it 
can be misleading to a gynaecological diagnosis. Non gynaecological diagnosis such as GIST must be considered in 
patients with pelvic mass presenting with atypical symptoms. 
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Introduction 
 
Gastrointestinal stromal tumour (GIST) is a rare 
condition, with a reported incidence of 20 per million 
per year. It is the most common mesenchymal tumour 
of the gastrointestinal tract. Histologically, it ranges 
from pure spindle cell neoplasm to epithelioid 
neoplasms. Historically, GIST was categorized as 
smooth muscle tumours.  Thus, smooth muscle 
tumours histologically comprising spindle cells, 
arising in the pelvis may easily be mistaken with a 
gynaecological disorder such as uterine fibroid or 
ovarian fibroma. We report a diagnostically 




A 49-year-old, nulliparous teacher, complained of 
lower abdominal pain, with lethargy and pelvic mass. 
She was diagnosed to have severe iron deficiency 
anaemia secondary to heavy menstrual bleeding due to 
uterine fibroid at another centre four months prior, and 
was planned for hysterectomy. She later developed per 
rectal bleeding with diarrhea. Abdominal examination 
revealed a soft but tender abdomen with a mass of 14 
weeks size of gravid uterus. Full blood count showed 
mild leucocytosis, white cell count 13.4 x 10^9/l, 
haemoglobin 12.3g/dl and platelet 313 x 10^9/l. 
Tumor markers were not taken as the working 
diagnosis was uterine fibroid. Pelvic sonography noted 
an anteverted uterus with a 10.2 x 7.3cm solid cystic 
mass adherent to the anterior part of uterus (Fig. 1). 
Colonoscopy results were normal. CT scan findings 
noted that the mass was in continuity with the anterior 
part of uterus, suggestive of uterine fibroid. 
 
Our impression was cystic degeneration of fibroid. We 
counseled for surgery as the pain was worsening, 
namely for total abdominal hysterectomy bilateral 
salpingooopherectomy (TAHBSO) as she was 49 
years old with no fertility issue.  
 
Abdominal incision was via Pfannenstiel incision. 
There was a friable mass adherent to a segment of 
small bowel and to the anterior uterus (Fig. 2). Small 
bowel resection with primary anastomosis was 
performed by the surgical team followed by TAHBSO. 
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Figure 1: Transabdominal sonography (on the left) and transvaginal sonography (on the right) noted presence of a pelvic mass 
adherent to anterior uterus. 
 
 
Figure 2: A cut segment of the small bowel with the tumour 
growing extraluminally.  
 
Postoperative recovery was uncomplicated. HPE of the 
mass and the small bowel section showed malignant 
gastrointestinal tumour (GIST), high-risk category, 
whilst that of the uterus was leiomyomata with 
adenomyosis. Immunohistochemistry staining showed 
strong positivity for CD117 and DOG-1 with 
proliferative index for Ki-67 of 50%. Staining for 
CKAE1/AE3, smooth muscle actin and desmin were 
negative.  
 
She is currently under the oncology team follow-up. 
She was counselled for imatinib therapy with six 




GIST is extremely rare, with a reported incidence of 
20 per million per year, where 20-30% are malignant 
(1). It is the most common mesenchymal tumour of the 
gastrointestinal tract, the majority arising in the 
stomach. Even though GIST arises predominantly in 
the gastrointestinal tract, a small percentage (9%) 
arises extraintestinally (2). 
 
Histologically, it ranges from pure spindle cell 
neoplasm to epithelioid neoplasms. Historically, GIST 
was categorized as smooth muscle tumours.  Thus, 
smooth muscle tumours histologically comprising 
spindle cells, arising in the pelvis may easily be 
mistaken with a gynaecological disorder such as 
uterine leiomyoma or ovarian fibroma (3). However, 
with the advent of molecular therapies targeting 
CD117; also known as KIT proto-oncogene; GIST 
must be distinguished from smooth muscle tumours. 
Approximately, 90% of GIST tumors are strongly 
positive for KIT (CD117). A small percentage of GIST 
is KIT negative but is strongly positive for DOG1, a 
recently developed immunohistochemical marker 
which is relatively sensitive and specific for GIST. 
    
In this case, as the mass was adherent to the uterus, 
and it grew extraluminally from the small bowel, it 
created a diversion from the actual diagnosis.  
 
Literature review using PubMed have reported similar 
diagnostic dilemma. Two cases were reported by 
Morimura et al. (3), where patients were operated 
initially for suspected ovarian theco-fibroma and 
subserosal fibroma, however intraoperative findings 
and HPE confirmed GIST. Another author (4) also 
reported a case of suspected ovarian carcinoma, in a 
patient presenting with a large abdominal mass which 
on CT scan appeared to be multiseptated with ascites, 
turned out to be GIST.  
 
There is no recommendation at present regarding the 
best imaging modality to diagnose GIST. Most of the 
diagnoses were made either from intra-operatively or 
during histological examination. However, current 
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guidelines advocate CT scans as part of the initial 
evaluation and staging to detect distant metastases. 
MRI may also be useful in evaluation of rectal GIST 
for resectability (5). 
 
Initially, the mainstay treatment for localized GIST 
was complete surgical resection. However recently, 
Imatinib, an oral tyrosine kinase inhibitor, was 
introduced as an adjuvant therapy. Studies have shown 
a survival benefit of three years in high-risk patients; 5 
year survival rate of 92% with 3 years therapy versus 
81.7% with 1 year therapy (6,7). Currently, high-risk 
patients with risk of relapse should be offered adjuvant 
Imatinib as standard treatment (5). Unfortunately, it 




The rarity of GIST and the highly variable clinical 
presentations and appearances on radiological 
imaging, impose challenges in making the diagnosis. 
Gastrointestinal symptoms in a female patient with a 
pelvic mass must raise the suspicion of possible non-
gynaecological pathology, and differential diagnoses 
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